Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus ointment for chronic itchy eyes due to vernal keratoconjunctivitis
PACTR202206480800979Phase 4Not yet recruiting
- Sponsor
- Mahmoud Eltagoury
- Start
- Jul 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus in Vernal Keratoconjunctivitis (VKC) (2 arms), sponsored by Mahmoud Eltagoury. Primary endpoint: Improvement of manifestations of VKC. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on PACTR202206480800979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202206480800979.